Organisation paid for research Program year 2025 Source: CMS Open Payments

CenExel iResearch, LLC

Neither a doctor nor a teaching hospital

Research payments

$2,770,273

65 payments

Through program year 2025, CenExel iResearch, LLC is reported as receiving $2,770,273 in research payments, across 65 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $2,257,916 33
2024 Research $512,357 32

Breakdown

Who paid Research payments · program years 2024–2025
  1. E.R. Squibb & Sons, L.L.C. $1,794,242 15 payments
  2. Mylan Technologies Inc. $823,495 47 payments
  3. Merck Sharp & Dohme Corporation $152,536 3 payments
Studies the money was for Research payments · program years 2024–2025
  1. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $1,121,781 1 payment
  2. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $512,357 32 payments
  3. A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $311,138 15 payments
  4. An Open-Label, Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline with Immediate-release Trospium Chloride in Adolescents with Psychiatric Disorders $310,312 1 payment
  5. An Open-label, Phase 1, Single Ascending Dose Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of KarXT Intramuscular Formulations in Participants with Schizophrenia $276,478 1 payment
  6. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants with Opioid Use Disorder $151,188 1 payment
  7. A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder $48,487 2 payments
  8. A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder and Inadequate Response to Lithium, Valproate, or Lamotrigine $15,200 1 payment
  9. An Open-label, Phase 1, Single Ascending Dose Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of KarXT Intramuscular Formulations in Participants with Schizophrenia $4,641 1 payment
  10. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $4,032 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record